Navigation Links
Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up to 8 Hours

MIAMI, March 11 /PRNewswire/ -- Every day, 70 million Americans suffer from the aches and pains that come with arthritis and other chronic joint problems(1). One of the most effective ways to get fast relief from arthritis pain is the use of analgesic creams. The only problem is that the relief tends to be short-lived. Many people find that within 45 minutes to an hour and a half after applying a cream, the pain comes right back. RZN Nutraceuticals,, has solved that problem, with the development of their soothing, medicated and clinically tested analgesic Arthri-Zen Relief Cream(R). A recent randomized, blinded study found that Arthri-Zen Relief Cream(R) provides fast relief that is shown to last for up to eight hours.

The study recruited 83 adults with physician-diagnosed arthritis, all of whom had had a history of daily arthritis pain for a minimum of six months. For ten days, study subjects applied Arthri-Zen Relief Cream(R) to joint "hot spots" three times a day. They were evaluated by a clinician on the first day and again on the tenth day for conditions such as arthritis, inflammation, swelling, joint stiffness, muscle pain and range of motion. Throughout the study, participants also kept daily pain diaries.

The results were eye-opening: 63% of study subjects got relief from swelling, 93.8% experienced an increase in range of motion, 94.1% got relief from arthritis and inflammation and a full 100% had relief from muscle pain and joint stiffness. All of the results were statistically significant.

However, participants didn't have to wait 10 days to feel an effect. After just five minutes, over a quarter experienced 90-100% relief from their pain. Another 41.3% got 70-89% relief. And another 22.5% had 50-69% relief. The best part was that the relief lasted. Unlike other analgesic creams on the market, Arthri-Zen Relief Cream(R) provided relief from arthritis aches and pains for up to eight hours.

Long-lasting topical pain relief was the inspiration behind Arthri-Zen Relief Cream(R). "RZN Nutraceuticals decided to develop a pain relief cream because we weren't pleased with the length of relief provided by products that were currently on the market," said RZN Nutraceuticals President Robert Hunt. He should know. Hunt suffers from psoriatic arthritis, a debilitating form of arthritis. "I've tried them all...the Tiger Balms, the BenGays, the IcyHots...nothing lasts as long as this product."

Arthri-Zen Relief Cream(R) contains the OTC pain-relieving ingredient menthol, as well as RZN Nutraceuticals' all-natural, scientifically developed herbal formula featuring extracts of juniper, goldenrod, dandelion, meadowsweet and willow bark. All of those ingredients are delivered in a base with skin moisturizing conditioners such as aloe, shea butter, avocado and grape seed oil.

The same herbal formula used in the cream is featured in RZN Nutraceuticals' Arthri-Zen Relief(R) capsules, a dietary supplement that relieves arthritis pain in three specific ways: first, by blocking the transmission of pain signals; second, by reducing swelling in the joints; and third, by decreasing inflammation in the affected tissues.

Together, Arthri-Zen Relief Cream(R) and Arthri-Zen Relief(R) capsules form a complete program to successfully manage joint and muscle pain. The cream provides fast, convenient relief for arthritis "hot spots," while the capsules fight inflammation at its source for whole-body relief from pain.

Arthri-Zen Relief Cream(R) is not just limited to people with arthritis, though. It's also a favorite among athletes, as it quickly relieves the pain of backaches, sprains, bruises, strains and stiffness.

Currently, Arthri-Zen Relief Cream(R) is only available direct through the company's website or by phone at 904-213-8232. A 3 oz. tube retails for $19.95.

RZN Nutraceuticals is located in Miami, Florida. RZN Nutraceutical founder, Chief Scientist Mark Lubin is a biomedical engineer who has 12 U.S. patents issued or pending for biomedical and technical innovations.

For more information on Arthri-Zen Relief Cream(R) or any of RZN Nutraceuticals' products, please visit or call Robert Hunt at 904-213-8232. Media contact Renee Cooper of Christie Communications at 805-969-3744,

(1) Centers for Disease Control. "Prevalence of Self-Reported Arthritis or Chronic Joint Symptoms Among Adults --- United States, 2001." MMWR Weekly. Oct. 25, 2002;51(42):948-950.

SOURCE RZN Nutraceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
4. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
5. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
6. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
7. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
11. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
Breaking Medicine News(10 mins):